The Obesity Action Coalition (OAC) is pleased to share that Madrigal Pharmaceuticals, Inc. has joined OAC’s Chairman’s Council at the Bronze level! Thank you for committing to supporting and championing the OAC’s mission.

About Madrigal Pharmaceuticals, Inc.

Madrigal Pharmaceuticals, Inc. is a biopharmaceutical company pursuing novel therapeutics for nonalcoholic steatohepatitis (NASH), a liver disease with high unmet medical need. Madrigal’s medication, Rezdiffra (resmetirom), is a once-daily, oral, liver-directed THR-β agonist designed to target key underlying causes of NASH. For more information, visit

About the OAC Chairman’s Council

The OAC is honored that Madrigal Pharmaceuticals, Inc. has chosen to support our organization at the Bronze level through the Chairman’s Council as we strive to partner with industry leaders who share our mission of supporting and empowering individuals in their health journeys.

The OAC welcomes individuals, organizations or companies who wish to join our highest level of OAC Membership and receive maximum benefits. Our Chairman’s Council is an excellent way to give back to the cause and play an integral role in making the world a better place for people with obesity. To learn more about the OAC’s Chairman’s Council, click here.